From the Editor

Mar 01, 2011
Pharmaceutical Executive
Pharma can be an insular industry, with limited capacity to gaze beyond its own narrow frame of vision
Feb 04, 2011
Pharmaceutical Executive
"Tops in Fraud" is a ruinous moniker for pharma—a business so dependent on basic issues of trust, integrity, quality and safety
Jan 01, 2011
Pharmaceutical Executive
"Tops in Fraud" is a ruinous moniker for pharma—a business so dependent on basic issues of trust, integrity, quality and safety
Dec 01, 2010
Pharmaceutical Executive
The end of anther year is an appropriate time to highlight the march of time—and the transitions that accompany it
Nov 01, 2010
Pharmaceutical Executive
By Pharmaceutical Executive Editors
The FDA process itself is looking more like the unsavory 'sausage factory' associated with drafting partisan legislation
Oct 01, 2010
Pharmaceutical Executive
Adam Smith's theory of the uncompromising market may set the tone for today's capitalism, but we forget that his first work,"The Theory of Moral Sentiments," made 'bettering the human condition' the basis from which all productive commerce flows.
Sep 01, 2010
Pharmaceutical Executive
Reinvention takes more than a pithy redraft of the strategy plan or mission statement; money, a change in business culture, and the mindset of thousands of employees is required too
Aug 01, 2010
Pharmaceutical Executive
An industry struggling to meet expectations for new science may find the best strategy is the "controlled burn."
Jul 01, 2010
Pharmaceutical Executive
If there was ever a justification for endorsing a "triple bottom line" strategy for measuring Big Pharma's investment performance, it's the BP crisis.
Jun 01, 2010
Pharmaceutical Executive
Innovation in industry has always required a strong internal champion; the danger is a process led by the risk-adverse and externally-driven stakeholder consensus called "death by faint praise." Is this really what we mean by "bold partnerships?"
native1_300x100
lorem ipsum